Eupraxia Pharmaceuticals will showcase data from its RESOLVE trial at the upcoming ISDE World Congress for Esophageal Diseases in Edinburgh. The presentation will highlight the company’s innovative DiffuSphereTM technology, designed to improve drug delivery for a variety of conditions.
The global dual chamber prefilled syringes market is projected to experience significant growth, reaching a valuation of US$ 5,495.5 million by 2034, driven by rising demand for patient-centric healthcare solutions, increased convenience, and improved drug stability.
Cingulate Inc. (CING) shares are experiencing a surge on Friday, driven by the company’s announcement of a Precision Timed Release (PTR) technology designed to enhance ADHD drug delivery. The technology aims to improve the onset and efficacy of existing ADHD treatments, attracting investor interest. Zacks Small-Cap Research has also issued a positive note, valuing CING at $70. This article details CING’s price action, key metrics, and provides a guide on how to buy the stock.
